Antibodies against CD106 (VCAM-1)

Patent metadata

Field	Value
Publication number	US-10040854-B2
Application number	US-201314397074-A
Country	US
Kind code	B2
Filing date	Apr 24, 2013
Priority date	Apr 24, 2012
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

First claim

The invention claimed is:

1. A humanized antibody, or fragment thereof, comprising:
a heavy chain that comprises from the heavy chain variable region of SEQ ID NO:10, at least a CDR1 comprising TSGLG from SEQ ID NO:11, a CDR2 comprising VYWDDDK from SEQ ID NO:12, and a CDR3 comprising RAFYGNNGAYAMDY from SEQ ID NO:13, and
a light chain that comprises from the light chain variable region of SEQ ID NO:4 at least a CDR1 comprising QSISDY from SEQ ID NO:5, a CDR2 comprising YAS from SEQ ID NO:6, and a CDR3 comprising SEQ ID NO:7,
wherein the antibody or fragment thereof specifically binds human endothelial vascular cell adhesion molecule 1 (VCAM-1).

2. An antibody or fragment thereof according to claim 1 , wherein the antibody is a non-neutralising antibody.

3. An antibody according to claim 1 , wherein said antibody has a low affinity between 1 to 500 μM Kd.

4. An antibody according to claim 1 wherein the antibody is a monoclonal antibody.

5. An antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof comprises:
a light chain of SEQ ID NO: 3 or a light chain variable region amino acid sequence of SEQ ID NO: 4.

6. An antibody or fragment thereof according to claim 1 , wherein the antibody comprises:
(a) a heavy chain of SEQ ID NO: 9 or a heavy chain variable region amino acid sequence of SEQ ID NO: 10.

7. An antibody or fragment thereof according to claim 1 , wherein the antibody comprises the light chain variable region of SEQ ID NO: 4 and the heavy chain variable region of SEQ ID NO: 10.

8. An antibody or fragment thereof according to claim 1 , wherein the antibody comprises a light chain of SEQ ID NO: 3 and the heavy chain of SEQ ID NO: 9.

9. An antibody or fragment according to claim 1 wherein the antibody is conjugated to an iron oxide microparticle.

10. An antibody or fragment thereof according to claim 9 , wherein the antibody is conjugated to an iron oxide microparticle which is covalently bonded to other iron oxide microparticles by cleavable linker groups to form a multimeric particle.

11. An antibody or fragment thereof according to claim 1 , wherein the antibody binds to the extracellular domain of VCAM-1.

12. An antibody or fragment thereof according to claim 1 , wherein the antibody binds to VCAM-1 when expressed on endothelial cells.

13. A composition comprising the antibody or fragment thereof according to claim 1 .

14. The composition of claim 13 , wherein the antibody or fragment thereof is formulated in a pharmaceutically acceptable carrier.

Assignees

• Isis Innovation
• Univ Oxford Innovation Ltd

Inventors

• Anthony Daniel Clive
• Campbell Sandra Jane
• Carr Francis Joseph
• Choudhury Robin Patrick
• Davis Benjamin Guy
• Jones Timothy David
• Sibson Nicola Ruth

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K16/2836 Primary

  against CD106 · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• G01N2800/285

  Demyelinating diseases; Multipel sclerosis · CPC title

• G01N33/54346

  Nanoparticles · CPC title